Evidence map›Paper›PMID 42832145›Full record

ArticleAnnals of surgical oncology2026

Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.

Akira Hamada, Shinkichi Takamori, Asato Hashinokuchi, Mototsugu Shimokawa, Kenichi Suda, Shinya Katsumata, Naoki Haratake, Kotaro Nomura, Yoshihisa Shimada, Takahide Toyoda and 39 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Akira HamadaDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Shinkichi TakamoriDepartment of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, Oita, Japan.
Asato HashinokuchiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Kenichi SudaDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Shinya KatsumataDivision of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Naoki HaratakeDepartment of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, Oita, Japan.
Kotaro NomuraDepartment of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshihisa ShimadaDepartment of Surgery, Tokyo Medical University, Tokyo, Japan.
Takahide ToyodaDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Takuya WatanabeDivision of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Kazuki HayasakaDivision of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Masaoki ItoDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Shuta OharaDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Shota FukudaDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Tomoyo FukamiDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Hana OikiDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Kentaro MinegishiDepartment of Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Kantaro HaraDepartment of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Mao YoshikawaDepartment of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
Ken SuzawaDepartment of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
Kazuhiko ShienDepartment of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
Kosuke FujinoDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Takamasa KogaDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Keisuke KosaiDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Atsushi KamigaichiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Hirotsugu NotsudaDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Taichi MatsubaraDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shinya TaneDivision of Thoracic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyuki AbeDepartment of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, Oita, Japan.
Somei MatsuoDivision of Thoracic Surgery, Nihonkai General Hospital, Sakata, Japan.
Sho WakasuDepartment of Thoracic Surgery, NHO Kyushu Medical Center, Fukuoka, Japan.
Satoshi MutoDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Satoru OkadaDivision of Thoracic Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tomoki NishimuraDivision of Thoracic Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Michihito TodaDepartments of General Thoracic Surgery, Kansai Rosai Hospital, Japan Organization of Occupational Health and Safety, Hyogo, Japan.
Makoto EndoDepartment of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Kazuki TakadaDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Keigo SekiharaFirst Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Jun SuzukiDepartment of Surgery II, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Hikaru WatanabeDepartment of Surgery II, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Ryo FujikawaDepartment of Thoracic Surgery, Shimada General Medical Center, Shizuoka, Japan.
Hironobu HoshinoDepartment of Surgery, National Hospital Organization, Okinawa National Hospital, Okinawa, Japan.
Kazuhiko KuwaharaDepartment of Pathology and Genome Medical Center, Faculty of Medicine, Kindai University, Osaka, Japan.
Norihiko IkedaDepartment of Surgery, Tokyo Medical University, Tokyo, Japan.
Satoshi ShionoDepartment of Surgery II, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Junichi SohDepartment of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yasuhisa OhdeDivision of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yasuhiro TsutaniDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan. yatsutani@msn.com.ORCID http://orcid.org/0000-0001-8836-1027

Funding

Chugai Pharmaceutical jRCT1050240057
6 · The paper itself

Abstract

backgroundAlectinib was approved in 2024 as an adjuvant therapy for resected ALK-positive non-small-cell lung cancer (NSCLC) based on the ALINA trial. However, the role of cytotoxic adjuvant chemotherapy in this molecular subset remains uncertain. We evaluated the prognostic impact of cytotoxic adjuvant chemotherapy according to ALK status in patients with stage II-III lung adenocarcinoma.

methodsWe retrospectively analyzed 793 patients with pathologic stage II -III lung adenocarcinoma without EGFR mutations who underwent complete resection at 27 Japanese institutions. After propensity score matching (PSM) and inverse probability of treatment weighting (IPTW), we compared survival outcomes between the patients who received and did not receive cytotoxic adjuvant chemotherapy in the unadjusted cohort. Recurrence-free survival (RFS), overall survival (OS), and cumulative incidence of recurrence (CIR) were assessed.

resultsIn ALK-negative disease, cytotoxic adjuvant chemotherapy significantly improved RFS, OS, and CIR, both before and after PSM (unadjusted: RFS hazard ratio [HR] 0.67; 95% confidence interval [CI] 0.56-0.81; OS HR 0.55; 95% CI 0.43-0.71; CIR HR 0.74; 95% CI 0.61-0.90); similar favorable trends were observed after IPTW adjustment. Conversely, in ALK-positive disease, only OS showed a significant improvement in the unadjusted analysis (HR 0.19; 95% CI 0.04-0.81), whereas RFS and CIR did not differ significantly. After PSM and IPTW adjustment, similar overall trends were observed.

conclusionsThe prognostic impact of cytotoxic adjuvant chemotherapy differed by ALK status, suggesting limited efficacy in ALK-positive adenocarcinoma and supporting tailored postoperative strategies for this subset.

Indexed as

Adjuvant chemotherapyAnaplastic lymphoma kinase (ALK)Inverse probability of treatment weighting (IPTW)Non-small-cell lung cancer (NSCLC)Propensity score matching (PSM)

Identifiers

PMID42832145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.